Desvenlafaxine Tablet, Extended Release
Product Images NDC 70436-013

16 FDA label images from Slate Run Pharmaceuticals, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 70436-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Des Structure)

Chemical Structure (Des Structure)
Chemical structure diagram depicting the molecular formula of Desvenlafaxine, including its core aromatic ring and associated functional groups as shown in the image.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A forest plot chart showing the geometric mean ratio (90% confidence interval) of pharmacokinetic parameters Cmax and AUC for Desvenlafaxine across different levels of renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population subgroups based on gender and age (females, 65-75 years, >75 years). The x-axis represents the change relative to reference, ranging from 0.5 to 3.5.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A horizontal bar chart showing the geometric mean ratio (90% CI) for pharmacokinetic parameters Cmax and AUC of Desvenlafaxine when influenced by the CYP3A4 inhibitor Ketoconazole. The chart compares changes relative to a reference, with values approximately 1.08 for Cmax and 1.43 for AUC, each with confidence intervals displayed.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A forest plot chart showing geometric mean ratios (90% confidence intervals) of pharmacokinetic (PK) changes caused by Desvenlafaxine at various dosages (50 mg, 100 mg, 400 mg) on interacting drugs that are CYP2D6, CYP3A4, or both substrate types. Drugs represented include Desipramine, Midazolam, Tamoxifen, and Aripiprazole, with Cmax and AUC (area under the curve) or related PK parameters compared relative to reference values.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. Two groups are represented: Desvenlafaxine Extended-Release Tablets 50 mg (solid blue line) and Placebo (dashed red line). The graph compares relapse rates up to approximately 190 days.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A Kaplan-Meier curve graph comparing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph shows two lines: a solid blue line representing Desvenlafaxine Extended-Release Tablets and a dashed red line representing placebo. The y-axis ranges from 0 to 50 percent, and the x-axis ranges from 0 to 200 days, illustrating lower relapse rates over time for the Desvenlafaxine group compared to placebo.*
FDA Label Image

50 mg, 30 Ct (50mg 30ct Coo India)

50 mg, 30 Ct (50mg 30ct Coo India)
Label for Desvenlafaxine Extended-Release Tablets 50 mg by Slate Run Pharmaceuticals, LLC. The label states each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. The package contains 30 tablets. Storage instructions specify 20° to 25°C with permitted excursions.*
FDA Label Image

50 mg, 30 Ct (50mg 30ct Coo Malta)

50 mg, 30 Ct (50mg 30ct Coo Malta)
Label for Desvenlafaxine Extended-Release Tablets 50 mg by Slate Run Pharmaceuticals, LLC. The label shows storage instructions, contains 30 tablets, and includes a barcode. It states the tablets deliver 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. The label also instructs pharmacists to dispense a medication guide.*
FDA Label Image

50 mg, 90 Ct (50mg 90ct Coo India)

50 mg, 90 Ct (50mg 90ct Coo India)
Label for Desvenlafaxine Extended-Release Tablets 50 mg produced by Slate Run Pharmaceuticals, LLC. The label states each extended-release tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. Storage instructions, distributor information, package size of 90 tablets, and a barcode are also shown on the label.*
FDA Label Image

50 mg, 90 Ct (50mg 90ct Coo Malta)

50 mg, 90 Ct (50mg 90ct Coo Malta)
Label for Desvenlafaxine Extended-Release Tablets, 50 mg, oral dosage form by Slate Run Pharmaceuticals, LLC. The label states each extended-release tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. The package contains 90 tablets. Storage instructions and pharmacist dispensing information are included.*
FDA Label Image

100 mg, 30 Ct (100mg 30ct Coo India)

100 mg, 30 Ct (100mg 30ct Coo India)
Desvenlafaxine Extended-Release Tablets 100 mg label from Slate Run Pharmaceuticals, LLC. The label indicates each tablet contains 152 mg desvenlafaxine succinate equivalent to 100 mg desvenlafaxine. The package includes 30 tablets and instructs pharmacists to dispense the accompanying Medication Guide. Storage and distribution details are also provided.*
FDA Label Image

100 mg, 30 Ct (100mg 30ct Coo Malta)

100 mg, 30 Ct (100mg 30ct Coo Malta)
Desvenlafaxine Extended-Release Tablets 100 mg label showing an oral extended-release tablet by Slate Run Pharmaceuticals, LLC. The label includes dosage strength, NDC number 70436-013-04, storage instructions, and a 30-count tablet package. It instructs pharmacists to dispense the accompanying Medication Guide.*
FDA Label Image

100 mg, 90 Ct (100mg 90ct Coo India)

100 mg, 90 Ct (100mg 90ct Coo India)
Desvenlafaxine Extended-Release Tablets 100 mg label from Slate Run Pharmaceuticals, LLC. The label indicates each extended-release tablet contains 152 mg desvenlafaxine succinate equivalent to 100 mg desvenlafaxine. It shows storage instructions, a barcode, and states a package count of 90 tablets. The label notes the product is distributed by Slate Run Pharmaceuticals, LLC, made in India, and includes a revision date of 06/2025.*
FDA Label Image

100 mg, 90 Ct (100mg 90ct Coo Malta)

100 mg, 90 Ct (100mg 90ct Coo Malta)
Desvenlafaxine Extended-Release Tablets 100 mg label from Slate Run Pharmaceuticals, LLC. The label specifies each tablet contains 152 mg desvenlafaxine succinate equivalent to 100 mg desvenlafaxine. It indicates storage conditions, repackaging details, and contains a barcode. The package includes 90 tablets.*
FDA Label Image

25 mg, 30 Ct (25mg 30ct Coo India)

25 mg, 30 Ct (25mg 30ct Coo India)
Desvenlafaxine Extended-Release Tablets 25 mg label from Slate Run Pharmaceuticals, LLC. This prescription oral tablet contains 25 mg of desvenlafaxine per extended-release tablet. The label includes storage instructions, dosage details, and a package count of 30 tablets. Distributed by Slate Run Pharmaceuticals with a barcode on the right side.*
FDA Label Image

25 mg, 30 Ct (25mg 30ct Coo Malta)

25 mg, 30 Ct (25mg 30ct Coo Malta)
Label for Desvenlafaxine Extended-Release Tablets, 25 mg strength, oral dosage form. The label states each extended-release tablet contains 38 mg desvenlafaxine succinate equivalent to 25 mg desvenlafaxine. Distributed by Slate Run Pharmaceuticals, LLC, Columbus, Ohio. The package contains 30 tablets with storage instructions and a barcode. The label includes a pharmacist note to dispense the accompanying medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.